
Jan 12 (Reuters) - Eli Lilly and Co LLY.N:
RECLUDIX PHARMA : ANNOUNCES EQUITY FINANCING TO ADVANCE CLINICAL DEVELOPMENT OF NOVEL SH2 DOMAIN INHIBITORS
RECLUDIX PHARMA : FINANCING LED BY INSTITUTIONAL INVESTORS, WITH PARTICIPATION FROM NEW INVESTOR ELI LILLY AND COMPANY
RECLUDIX PHARMA : TOTAL OF $123 MILLION IN EQUITY FINANCING RECEIVED FROM INSTITUTIONAL AND STRATEGIC INVESTORS TO DATE
RECLUDIX PHARMA : ANNOUNCES COLLABORATION WITH LILLY TO UTILIZE LILLY TUNELAB TO ACCELERATE DEVELOPMENT OF RECLUDIX’S DISCOVERY PIPELINE